Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Exclusivity On Delisted Patents Upheld By Appeals Court

This article was originally published in The Pink Sheet Daily

Executive Summary

In ruling on the Zocor case, court finds FDA requirement that a generic company must be involved in patent litigation to retain exclusivity is unlawful.

You may also be interested in...



Teva Sues FDA To Relist Risperdal Patent

J&J scenario differs from Merck's Zocor fight, attorney tells “The Pink Sheet” DAILY.

Teva Sues FDA To Relist Risperdal Patent

J&J scenario differs from Merck's Zocor fight, attorney tells “The Pink Sheet” DAILY.

Teva And Ranbaxy Launch Generic Zocor With 180-Day Exclusivity

Despite an eleventh-hour suit by Sandoz, FDA approved the generic companies’ ANDAs for simvastatin.

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel